Neoplasms by Site Recruiting Phase 1 / 2 Trials for Nivolumab (DB09035)

IndicationStatusPhase
DBCOND0030096 (Neoplasms by Site)Recruiting1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03656718A Study of Subcutaneous Nivolumab Monotherapy With or Without Recombinant Human Hyaluronidase PH20 (rHuPH20)Treatment